Major Players in the Women’s Health Diagnostics Market Pursue Strategies of Mergers, Acquisitions, Partnerships, Agreements, and Collaborations to Strength Their Position in the Market

According to the new market research report “Womens Health Diagnostics Market by application (Prenatal Testing, Down Syndrome, HPV, Fertility Test, Pregnancy Test, Urinary Tract Infections, Osteoporosis, Breast, Cervical and Ovarian Cancer Test) End User (Hospitals, Home Care) - Forecast to 2021", published by MarketsandMarkets™, The global women’s health diagnostics market is projected to reach USD 36.64 Billion by 2021 from USD 25.03 Billion in 2016, at a CAGR of around 7.9% during the forecast period.


In this report, the global women health diagnostics market is segmented on the basis of application and end user. On the basis of application, the market is segmented into nine segments namely, osteoporosis testing, ovarian cancer testing, cervical cancer testing, breast cancer testing, pregnancy & ovulation testing, prenatal genetic screening & carrier testing, infectious disease testing, sexually transmitted disease testing, and ultrasound. The osteoporosis segment is further divided into bone densitometry and in vitro blood tests. The ovarian cancer segment is divided into tumor marker tests, diagnostic imaging tests and others. The cervical cancer segment is sub segmented into PAP smear testing and HPV testing. The breast cancer testing segment is further divided into mammography, tumor marker tests, blood cell count & blood chemistries, biopsies and other diagnostic imaging tests. Pregnancy and fertility testing market is sub segmented into lab-based testing, pregnancy self-test and ovulation prediction kits, ovulation prediction kits, fertility monitors and thermometers. The prenatal genetic screening & carrier testing segment is further divided into cystic fibrosis, Down syndrome and Edward syndrome, TORCH infections and others (fragile x-syndrome & tay-sachs diseases).
Further on, the infectious disease testing market segment is sub segmented into methicillin-resistant staphylococcus aurea (MRSA), urinary tract infections (vaginal pH & vaginitis), hepatitis, tuberculosis, and others infectious disease testing. The sexually transmitted disease testing segment comprises Chlamydia Trachomatis and Neisseria Gonorrohoeae testing, HIV testing and other STD testing. The ultrasound segment covers breast imaging and ob/gyn imaging. On the basis of end user, the women’s health diagnostics market is segmented into hospitals & clinics, home care, and diagnostic & imaging centers.
Women's Health Diagnostics Market

Major players in the global women’s health diagnostics market are Siemens AG (Germany), Quest Diagnostics Inc. (U.S.), Hologic, Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), PerkinElmer Inc. (U.S.), Alere Inc. (U.S.), GE Healthcare (U.S.), Becton, Dickinson and Company (BD) (U.S.), Abbott Laboratories (U.S.), bioMérieux SA (France), and Koninklijke Philips N.V. (Netherlands).
Location: Dundee Rd, Illinois, USA

Comments

Post a Comment

Popular posts from this blog

Key Players in the Pyrogen Testing Market Focus on Partnerships, Agreements, & Collaborations, Acquisitions, New Product launches, and Expansions

Image
The report  " Pyrogen Testing Market  by Product (Instruments, Services, Kits and Reagents), Application (Pharmaceutical & Biotechnology, Medical Devices, Other), & by Test (In Vitro, LAL, Gel Clot, Turbidimetric, Chromogenic, Rabbit) - Global Forecasts to 2021 " ,  report provides a detailed overview of the major drivers, restraints, opportunities, current market trends, and strategies impacting the global pyrogen testing market along with the estimates and forecasts of the revenue and market share analysis. Speak to Analyst @  https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=255266155 The global pyrogen testing market is valued at $462.38 million in 2014 and is expected to grow at a CAGR of 12.23%, to reach $823.14 million by 2019. Pyrogen testing is used to determine the bacterial toxins in products intended for medical or veterinary use. Rapidly growing pharmaceutical and biotechnology industries are a major growth driver for this market. Further
Read more

Non Invasive Prenatal Testing Market| Market Trends by Instruments, Consumables, Method, Application and End User

The major factors driving the growth of this market include the growing preference for non-invasive techniques over invasive methods, rising focus on reimbursement for NIPT, launch of new and advanced NIPT products, and increasing maternal age (associated with growth in the risk of chromosomal abnormalities in babies). Furthermore, untapped emerging markets are expected to offer potential growth opportunities to players operating in the NIPT market during the forecast period. The non-invasive prenatal testing (NIPT) market is expected to reach USD 2.88 billion by 2021 from USD 1.35 billion in 2016, at a CAGR of 16.4% from 2016 to 2021. The instruments segment is divided into ultrasound device, NGS systems, PCR instruments, microarrays, and other instruments. In 2016, the consumables segment accounted for the largest share of the market. The high growth in this segment is attributed to the repeated requirements of consumables as compared to instruments in NIPT. Based on application
Read more

Global Glycomics Market Players Pursue the Strategies of Product Launches, Agreements, Expansions, Acquisitions, and Collaborations

Image
The major players in this market include Agilent Technologies (U.S.), Bruker Corp. (U.S.), Danaher Corp. (U.S.), New England Biolabs (U.S.), Prozyme Inc. (U.S.), Shimadzu Corp. (Japan), Sigma-Aldrich Corp. (U.S.), Takara Bio (Japan), Thermo Fisher Scientific (U.S.), and Waters Corp. (U.S.). The glycomics market is dominated by a few major players, with the top five players accounting for a majority of the market share. The top four players for glycomics enzymes, kits, and reagents have a combined market share of about 75.2% and for glycomics instruments have a combined market share of about 76.0%. The global glycomics market is highly evolved, with multiple different product segments. An analysis of market developments between 2011 and 2014 revealed that new product launches was the most important growth strategy employed by market leaders in this period. This strategy was adopted by most players in this market, except New England Biolabs (U.S.) and Takara Bio, Inc. (Japan).
Read more